Boston Scientific Corporation $BSX Stock Purchased by PBU The Pension Fund of Early Childhood & Youth Educators

PBU The Pension Fund of Early Childhood & Youth Educators increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 18.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 263,677 shares of the medical equipment provider’s stock after buying an additional 41,713 shares during the quarter. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Boston Scientific were worth $11,510,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific during the 2nd quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the first quarter valued at about $28,000. Nvwm LLC increased its position in Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 542 shares during the last quarter. Rakuten Securities Inc. acquired a new stake in Boston Scientific during the second quarter worth about $30,000. Finally, Kings Path Partners LLC purchased a new position in Boston Scientific during the third quarter worth about $31,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. TD Cowen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating and decreased their target price for the company from $56.00 to $46.00 in a report on Friday, October 30th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Needham & Company LLC decreased their price objective on Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. Oppenheimer lowered Boston Scientific from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 29th. Finally, Stifel Nicolaus cut their target price on Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Stock Down 2.0%

Boston Scientific stock opened at $44.22 on Friday. The company has a market capitalization of $64.10 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 1.34 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. Boston Scientific Corporation has a fifty-two week low of $39.57 and a fifty-two week high of $105.65. The firm has a 50 day moving average price of $44.05 and a 200 day moving average price of $54.75.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the business posted $0.75 earnings per share. Research analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.